|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||-2.94|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Orgenesis Inc. , a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing, today announced that it will be presenting at the ...
BASEL, Switzerland and CAMBRIDGE, Mass. and GOSSELIES, Belgium, June 06, 2017-- CRISPR Therapeutics AG, a leader in gene-editing based therapeutics, and MaSTherCell SA, a full service contract development ...
Categories: Yahoo FinanceGet free summary analysis Orgenesis, Inc. reports financial results for the quarter ended February 28, 2017. Highlights Summary numbers: Revenues of USD 1.85 million, Net Earnings of USD -9.00 million. Gross margins narrowed from -18.95% to -23.43% compared to the same period last year, operating (EBITDA) margins now -154.10% from -79.87%. Change in operating cash ... Read more (Read more...)